OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation

Executive Summary

• OrganOx Ltd. completed its acquisition by Terumo Corporation, becoming a wholly‑owned subsidiary.
• The transaction enables accelerated R&D, expansion of the metra® platform beyond liver transplantation, and broader global commercial reach via Terumo’s network.
• Management highlights that the deal positions both companies to serve more patients worldwide and drive future growth.

Key Details

• Acquisition announced originally on August 25 2025; all customary regulatory and closing conditions have now been satisfied.
• Post‑closing, OrganOx will operate under Terumo ownership, leveraging Terumo’s scale and expertise in medical innovation.
• The combined entity plans to invest in research and development to evolve the OrganOx metra® platform technology beyond liver applications.
• Expansion of normothermic machine perfusion (NMP) use for organ support and enhancement is a strategic focus.
• Terumo’s global network will be utilized to accelerate commercial expansion, deepen presence in existing regions, and open new markets worldwide.
• CEO Craig Marshall emphasized the partnership’s potential to increase patient access to organ‑preservation technologies and drive growth.

Notable Quotes

“Our mission has always been to create a world where every organ counts. Joining Terumo will accelerate our ability to scale our operations more rapidly, enter new markets and ensure that more patients around the globe can benefit from our technologies.” – Craig Marshall, CEO, OrganOx

“This milestone reflects the extraordinary dedication of our team… With Terumo’s partnership, we’re positioned to deliver even greater growth and impact.” – Craig Marshall, CEO, OrganOx